US20100022642A1 - Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide - Google Patents
Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide Download PDFInfo
- Publication number
- US20100022642A1 US20100022642A1 US12/318,938 US31893809A US2010022642A1 US 20100022642 A1 US20100022642 A1 US 20100022642A1 US 31893809 A US31893809 A US 31893809A US 2010022642 A1 US2010022642 A1 US 2010022642A1
- Authority
- US
- United States
- Prior art keywords
- dermatological
- cosmetic composition
- cellulose
- benzoyl peroxide
- gelling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 113
- 239000004342 Benzoyl peroxide Substances 0.000 title claims abstract description 72
- 235000019400 benzoyl peroxide Nutrition 0.000 title claims abstract description 72
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 title claims abstract description 64
- 239000002537 cosmetic Substances 0.000 title claims abstract description 36
- 150000004492 retinoid derivatives Chemical class 0.000 title claims abstract description 28
- 150000001875 compounds Chemical class 0.000 claims abstract description 30
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 48
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 36
- 239000003349 gelling agent Substances 0.000 claims description 33
- 229920002678 cellulose Polymers 0.000 claims description 23
- 239000001913 cellulose Substances 0.000 claims description 23
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims description 22
- 229960002916 adapalene Drugs 0.000 claims description 21
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 claims description 18
- 150000004676 glycans Chemical class 0.000 claims description 17
- 229920001282 polysaccharide Polymers 0.000 claims description 17
- 239000005017 polysaccharide Substances 0.000 claims description 17
- 206010000496 acne Diseases 0.000 claims description 16
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 15
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 14
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 12
- 229920002507 Poloxamer 124 Polymers 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 229940093448 poloxamer 124 Drugs 0.000 claims description 12
- 239000000230 xanthan gum Substances 0.000 claims description 12
- 229920001285 xanthan gum Polymers 0.000 claims description 12
- 235000010493 xanthan gum Nutrition 0.000 claims description 12
- 229940082509 xanthan gum Drugs 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 9
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 8
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 238000009736 wetting Methods 0.000 claims description 7
- 229910052782 aluminium Inorganic materials 0.000 claims description 6
- -1 aluminum silicates Chemical class 0.000 claims description 6
- 230000003780 keratinization Effects 0.000 claims description 6
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 5
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 5
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 5
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000391 magnesium silicate Substances 0.000 claims description 5
- 150000004760 silicates Chemical class 0.000 claims description 5
- HCWCAKKEBCNQJP-UHFFFAOYSA-N magnesium orthosilicate Chemical compound [Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-] HCWCAKKEBCNQJP-UHFFFAOYSA-N 0.000 claims description 4
- 235000019792 magnesium silicate Nutrition 0.000 claims description 4
- 229910052919 magnesium silicate Inorganic materials 0.000 claims description 4
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 230000024245 cell differentiation Effects 0.000 claims description 3
- 230000004663 cell proliferation Effects 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 210000004209 hair Anatomy 0.000 claims description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 230000000254 damaging effect Effects 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 230000003659 hair regrowth Effects 0.000 claims description 2
- 229920003063 hydroxymethyl cellulose Polymers 0.000 claims description 2
- 229940031574 hydroxymethyl cellulose Drugs 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 230000003658 preventing hair loss Effects 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 1
- 239000011777 magnesium Substances 0.000 claims 1
- 229910052749 magnesium Inorganic materials 0.000 claims 1
- 229960000502 poloxamer Drugs 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 description 15
- 210000003491 skin Anatomy 0.000 description 11
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000013543 active substance Substances 0.000 description 8
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 6
- 229920002125 Sokalan® Polymers 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 229920003111 hydroxyethyl cellulose HHX Polymers 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- MRRTWUTXDYFAEU-UHFFFAOYSA-N 6-[4-methoxy-3-(2-methylundecan-2-yl)phenyl]naphthalene-2-carboxylic acid Chemical compound C1=C(OC)C(C(C)(C)CCCCCCCCC)=CC(C=2C=C3C=CC(=CC3=CC=2)C(O)=O)=C1 MRRTWUTXDYFAEU-UHFFFAOYSA-N 0.000 description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010003645 Atopy Diseases 0.000 description 2
- LDGIHZJOIQSHPB-UHFFFAOYSA-N CD437 Chemical compound C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1O LDGIHZJOIQSHPB-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010016936 Folliculitis Diseases 0.000 description 2
- 229920003091 Methocel™ Polymers 0.000 description 2
- 208000000260 Warts Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 229960001727 tretinoin Drugs 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 238000004383 yellowing Methods 0.000 description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- DWHIUNMOTRUVPG-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCO DWHIUNMOTRUVPG-UHFFFAOYSA-N 0.000 description 1
- SGRCVQDBWHCTIS-UHFFFAOYSA-N 2-nonanoyloxypropyl nonanoate Chemical compound CCCCCCCCC(=O)OCC(C)OC(=O)CCCCCCCC SGRCVQDBWHCTIS-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 1
- IICAATBTLIACJN-UHFFFAOYSA-N 6-(3,4-dimethoxyphenyl)naphthalene-2-carboxylic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC=C(C=C(C=C2)C(O)=O)C2=C1 IICAATBTLIACJN-UHFFFAOYSA-N 0.000 description 1
- LGLGUPSRYHIKFN-UHFFFAOYSA-N 6-(3-methylphenyl)naphthalene-2-carboxylic acid Chemical compound CC1=CC=CC(C=2C=C3C=CC(=CC3=CC=2)C(O)=O)=C1 LGLGUPSRYHIKFN-UHFFFAOYSA-N 0.000 description 1
- STKORMCWOLKUMM-UHFFFAOYSA-N 6-(3-tert-butylphenyl)naphthalene-2-carboxylic acid Chemical compound CC(C)(C)C1=CC=CC(C=2C=C3C=CC(=CC3=CC=2)C(O)=O)=C1 STKORMCWOLKUMM-UHFFFAOYSA-N 0.000 description 1
- LHHLQVLCOOFYHE-UHFFFAOYSA-N 6-(4-tert-butylphenyl)naphthalene-2-carboxylic acid Chemical compound C1=CC(C(C)(C)C)=CC=C1C1=CC=C(C=C(C=C2)C(O)=O)C2=C1 LHHLQVLCOOFYHE-UHFFFAOYSA-N 0.000 description 1
- IQGUQZKSRAZHBG-UHFFFAOYSA-N 6-[4-(1-adamantylsulfanyl)phenyl]naphthalene-2-carboxylic acid Chemical compound C1C(C2)CC(C3)CC2CC13SC(C=C1)=CC=C1C1=CC2=CC=C(C(=O)O)C=C2C=C1 IQGUQZKSRAZHBG-UHFFFAOYSA-N 0.000 description 1
- 239000013531 ACULYN rheology modifier Substances 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical class NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940124091 Keratolytic Drugs 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229920003102 Methocel™ E4M Polymers 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- PVLJETXTTWAYEW-UHFFFAOYSA-N Mizolastine Chemical compound N=1C=CC(=O)NC=1N(C)C(CC1)CCN1C1=NC2=CC=CC=C2N1CC1=CC=C(F)C=C1 PVLJETXTTWAYEW-UHFFFAOYSA-N 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 description 1
- 229920002509 Poloxamer 182 Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000034527 Retinoid X Receptors Human genes 0.000 description 1
- 241001303601 Rosacea Species 0.000 description 1
- 208000015390 Sebaceous gland disease Diseases 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 241000208292 Solanaceae Species 0.000 description 1
- 206010042731 Sycosis barbae Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010056131 Tinea versicolour Diseases 0.000 description 1
- 241000934136 Verruca Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003254 anti-foaming effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 229960004311 betamethasone valerate Drugs 0.000 description 1
- SNHRLVCMMWUAJD-SUYDQAKGSA-N betamethasone valerate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CCCC)[C@@]1(C)C[C@@H]2O SNHRLVCMMWUAJD-SUYDQAKGSA-N 0.000 description 1
- 235000020682 bottled natural mineral water Nutrition 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 description 1
- 229960001083 diazolidinylurea Drugs 0.000 description 1
- KORSJDCBLAPZEQ-UHFFFAOYSA-N dicyclohexylmethane-4,4'-diisocyanate Chemical compound C1CC(N=C=O)CCC1CC1CCC(N=C=O)CC1 KORSJDCBLAPZEQ-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LAWOZCWGWDVVSG-UHFFFAOYSA-N dioctylamine Chemical compound CCCCCCCCNCCCCCCCC LAWOZCWGWDVVSG-UHFFFAOYSA-N 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 235000004626 essential fatty acids Nutrition 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 208000009197 gingival hypertrophy Diseases 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 208000002557 hidradenitis Diseases 0.000 description 1
- 201000007162 hidradenitis suppurativa Diseases 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 230000001530 keratinolytic effect Effects 0.000 description 1
- 239000003410 keratolytic agent Substances 0.000 description 1
- 229940031674 laureth-7 Drugs 0.000 description 1
- 208000002741 leukoplakia Diseases 0.000 description 1
- 235000012243 magnesium silicates Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229960002509 miconazole Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 229960001144 mizolastine Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 208000008588 molluscum contagiosum Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 201000008743 palmoplantar keratosis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 229940093426 poloxamer 182 Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001185 psoriatic effect Effects 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 201000004700 rosacea Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 150000003408 sphingolipids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/38—Percompounds, e.g. peracids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/731—Cellulose; Quaternized cellulose derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/008—Preparations for oily skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/008—Preparations for oily hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- the present invention relates to dermatological/cosmetic compositions comprising, formulated into a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system which comprises at least two particular categories of compounds.
- corticosteroids such as, for example hydrocortisone, miconazole or betamethasone valerate, antihistamines (e.g., mizolastine) and/or keratolytic agents such as salicylic acid.
- antihistamines e.g., mizolastine
- keratolytic agents such as salicylic acid.
- anti-fungal agents such as allylamine derivatives, triazoles, anti-bacterial or anti-microbial agents such as, for example, antibiotics, quinolones and imidazoles are also conventionally combined in the treatment of dermatological diseases.
- Peroxides, D vitamins and retinoids are also described for the topical treatment of various pathologies associated with the skin or mucous membranes, in particular acne.
- the advantage is therefore understood in seeking to obtain a novel treatment that is effective on dermatological conditions, that has a stable composition offering good cosmetic quality, allowing a single application and administration that is pleasant for the patient.
- benzoyl peroxide is linked to its decomposition when it is placed in contact with skin. Indeed, it is the oxidizing properties of the free radicals produced during this decomposition that result in the desired effect. Thus, in order to maintain an optimal effectiveness of the benzoyl peroxide, it is important to prevent its decomposition before use, that is to say during storage.
- benzoyl peroxide is an unstable chemical compound which makes its formulation in finished products difficult.
- This document furthermore specifies that the stability of benzoyl peroxide is strongly influenced by the chemical composition of the formulation and by the storage temperature.
- Benzoyl peroxide is extremely reactive and degrades in solution at low temperature due to the instability of its peroxide bond.
- the degradation times of benzoyl peroxide in PEG 400 are respectively 1.4, 29 and 53 days at 40° C. Such a degradation does not allow the preparation of a product useful for sale.
- benzoyl peroxide is more stable in water and propylene glycol when it is in suspension (i.e., in dispersed form), as it is not degraded after being kept for 90 days in these solvents.
- the presence of the formulation based on benzoyl peroxide causes a very rapid degradation of the oxidation-sensitive retinoids: it is calculated that 50% of the tretinoin is degraded in 2 hours and 95% in 24 hours. In the composition in which the retinoid is adapalene, no degradation of the adapalene was measured over 24 hours.
- a finished product in particular when it is a pharmaceutical or cosmetic composition, must maintain, throughout its shelf life, precise physicochemical criteria that make it possible to guarantee its pharmaceutical or cosmetic quality respectively.
- rheological properties it is necessary that the rheological properties be retained. They define the behavior and texture of the composition during application, but also the release properties of the active principle [1998 SFSTP Commission Report] and the homogeneity of the product when the active principles are present therein in the dispersed state.
- the formulation of benzoyl peroxide and a retinoid in gel form is advantageous for topical treatments, such as those of acne, as it especially avoids maintaining a greasy feel on the skin.
- Another difficulty to be overcome for preparing a composition especially comprising benzoyl peroxide, when it is in gel form, is that the gelling agents are destabilized by the benzoic acid released during the degradation of benzoyl peroxide.
- compositions have now surprisingly been developed satisfying this need, which comprise dispersed, free or encapsulated benzoyl peroxide, at least one retinoid and a gelling system comprising at least two categories of compounds, such compositions having good physical stability, that is to say not having a drop in viscosity over time and at ambient temperature (from 20 to 30° C.), and maintaining good chemical stability of the two active agents (benzoyl peroxide and retinoid). In particular, no degradation of the active agents is observed over time and/or at ambient temperature.
- compositions especially pharmaceutical compositions, comprising, formulated into a physiologically acceptable medium:
- a gelling system which comprises at least two categories of compounds
- said categories of compounds being selected from among silicates, cellulose gelling agents and polysaccharide gums, with the proviso that when at least two gelling agents are selected from among aluminum/magnesium silicate, xanthan gum and hydroxypropyl cellulose, the gelling system is composed of these two gelling agents, or comprises at least one gelling agent different from these three compounds.
- gelling system means a combination of gelling compounds that gives the composition a sufficient viscosity to maintain the retinoid and the benzoyl peroxide in suspension, even under the influence, in particular, of a pH variation due to the release of benzoic acid by the benzoyl peroxide.
- physiologically acceptable medium means a medium that is compatible with the skin, the mucous membranes and/or the integuments.
- compositions according to the invention are preferably in the form of an aqueous gel, which is particularly well suited to the target pathologies.
- a gel is a system comprising at least one phase (in general one or two phases), which is thermodynamically stable, resulting from the coagulation of a colloidal solution into a three-dimensional network. More specifically, an aqueous gel corresponds to a composition containing, in an aqueous phase, a visco-elastic mass formed from colloidal suspensions.
- the gelling system comprises at least two categories of compounds, naturally different and distinct, said categories of compounds being selected from among silicates, cellulose gelling agents and polysaccharide gums.
- silicate is understood in particular to mean clay derivatives, more specifically aluminum and magnesium silicates.
- the silicates are generally obtained from mineral clays having a crystalline lattice that are dissolved and purified in water to optimize the purity and effectiveness of the product. These compounds are especially marketed by R. T. Vanderbilt under the trademark VEEGUM® (for example: VEEGUM® HV or VEEGUM® K).
- the amount of silicate may vary over a wide range and depends in particular on the desired viscosity and on the other gelling agent and/or agents present in the composition.
- the silicate may be present in the composition according to the invention in concentrations from 0.1 to 10%, preferably ranging from 0.1 to 5% by weight relative to the total weight of the composition.
- the amount is from 0.5 to 2%, even more preferably from 0.8 to 1.8%, such as for example 1%, relative to the total weight of the composition.
- cellulose gelling agent means water-soluble polymers derived from cellulose. These polymers form water-soluble ethers (semi-synthetic cellulose) originating from viscous solutions after dissolving in an aqueous solution.
- cellulose polymers especially exemplary are methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxylpropyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose.
- hydroxypropylmethyl cellulose or hydroxyethyl cellulose are used. These compounds are especially marketed by Dow Chemical under the trademark METHOCEL® (for example: METHOCEL® E4M) or by Hercules under the trademark NATROSOL® (for example: NATROSOL® 250 HHX).
- the amount of cellulose gelling agent may vary over a wide range and in particular depends on the desired viscosity and on the other gelling agent and/or agents present in the composition.
- the cellulose-based gelling agent may be present in the composition according to the invention in amounts from 0.1 to 10%, preferably ranging from 0.1 to 5% by weight relative to the total weight of composition.
- the amount is from 0.5 to 2%, such as for example 0.5%, 1%, 1.5% or 2% relative to the total weight of the composition.
- Polysaccharide gums are complex mixtures of several high-molecular weight polysaccharides obtained by exudation from certain plants.
- polysaccharide gums non-limiting examples thereof are gum Arabic, gum tragacanth and xanthan gum, amongst another marketed by CP Kelco under the trademark XANTURAL® (for example: XANTURAL® 180).
- the amount of polysaccharide gum may vary over a wide range and depends in particular on the desired viscosity and on the other gelling agent and/or agents present in the composition.
- the polysaccharide gum may be present in the composition according to the invention in amounts from 0.01 to 5%, preferably ranging from 0.05 to 2% by weight relative to the total weight of the composition.
- the amount is from 0.1 to 0.8% such as, for example, 0.1%, 0.2% or 0.5% relative to the total weight of the composition.
- the gelling system may comprise two categories of compounds or three categories of compounds, said categories of compounds being selected from among silicates, cellulose gelling agents and polysaccharide gums.
- the gelling system comprising two categories of compounds comprises at least one cellulose gelling agent (in particular hydroxypropylmethyl cellulose or hydroxyethyl cellulose) in combination with a silicate or a xanthan gum, taking into account the condition indicated above.
- cellulose gelling agent in particular hydroxypropylmethyl cellulose or hydroxyethyl cellulose
- the gelling system comprising two categories of compounds comprises at least one silicate, in combination with a polysaccharide gum, taking into account the condition indicated above.
- the gelling system comprising two categories of compounds comprises at least one polysaccharide gum, in combination with a cellulose gelling agent (in particular hydroxypropylmethyl cellulose or hydroxyethyl cellulose), taking into account the condition indicated above.
- a cellulose gelling agent in particular hydroxypropylmethyl cellulose or hydroxyethyl cellulose
- the gelling system may also comprise at least one silicate, at least one cellulose gelling agent and at least one polysaccharide gum, taking into account the condition indicated above.
- gelling systems having three categories of compounds especially exemplary is the combination of polysaccharide gum, silicate and a cellulose gelling agent, taking into account the condition indicated above.
- the subject compositions may, in addition, comprise an additional gelling agent which may especially be selected from among mixtures of polyacrylamides such as the sodium acryloyidimethyltaurate copolymer/isohexadecane/polysorbate 80 mixture marketed under the trademark SIMULGEL 600 by Seppic, the polyacrylamide/C13-14 isoparaffin/laureth-7 mixture such as, for example, that marketed under the trademark SEPIGEL 305 by Seppic, the family of acrylic polymers coupled to hydrophobic chains such as the PEG-150/decyl/SMDI copolymer marketed under the trademark ACULYN 44 (polycondensate comprising at least, as components, a polyethylene glycol having 150 or 180 moles of ethylene oxide, decyl alcohol and methylenebis(4-cyclohexylisocyanate) (SMDI), at 35% by weight in a mixture of propylene glycol (39%) and water (26%)), the family of polyacrylamides such as
- compositions according to the invention contain at least one retinoid.
- retinoid means any compound that binds to RAR and/or RXR receptors.
- the retinoid is a compound selected from among the family of benzonaphthalenic retinoids as described in EP 0 199 636, and especially:
- adapalene and also its salts will be preferred.
- adapalene salts means the salt formed with a pharmaceutically acceptable base, especially mineral bases such as sodium hydroxide, potassium hydroxide and ammonia or organic bases such as lysine, arginine or N-methylglucamine.
- adapalene salts is also understood to mean the salts formed with fatty amines such as dioctylamine and stearylamine.
- retinoids may be selected from among those described in the following patents or patent applications: U.S. Pat. Nos. 4,666,941, 4,581,380, EP 0 210 929, EP 0 232 199, EP 0 260 162, EP 0 292 348, EP 0 325 540, EP 0 359 621, EP 0 409 728, EP 0 409 740, EP 0 552 282, EP 0 584 191, EP0 514 264, EP0 514 269, EP0 661 260, EP0 661 258, EP 0 658 553, EP 0 679 628, EP 0 679 631, EP 0 679 630, EP 0 708 100, EP 0 709 382, EP 0 722 928, EP 0 728 739, EP 0 732 328, EP 0 740 937, EP 0 776 885, EP 0 776 881, EP 0 823 903, EP 0 832 057, EP
- the amount of the two active agents, benzoyl peroxide and retinoid, in the composition according to the invention will depend on the combination selected and therefore particularly on the retinoid in question and on the quality of the desired treatment.
- the preferred retinoid concentrations are from 0.0001 to 20% by weight relative to the total weight of the composition.
- Benzoyl peroxide could also be used in the free form or else in an encapsulated form in a form adsorbed on, or absorbed in, any porous support.
- compositions according to the invention advantageously comprise from 0.0001 to 20% by weight of benzoyl peroxide and from 0.0001 to 20% by weight of retinoid relative to the total weight of the composition, and preferably, respectively, from 0.025 to 10% by weight of benzoyl peroxide and from 0.001 to 10% by weight of retinoid relative to the total weight of the composition.
- benzoyl peroxide is preferably present at concentrations ranging from 2 to 10% by weight and more particularly from 2.5 to 5% by weight relative to the total weight of the composition.
- Retinoid is itself present in this type of composition at concentrations generally ranging from 0.05 to 1% by weight relative to the total weight of the composition.
- the particle size of the retinoid and of the benzoyl peroxide is such that at least 80% by number of particles, and preferably at least 90% by number of particles, have a diameter of less than 25 ⁇ m and at least 99% by number of particles have a diameter of less than 100 ⁇ m.
- the gel containing the benzoyl peroxide and a retinoid comprises at least water and may also comprise a propenetrating agent and/or a wetting liquid surfactant.
- compositions of the invention may contain one or more propenetrating agents in preferable concentrations ranging from 0.01 to 20% to more preferably ranging from 2 to 6% by weight relative to the total weight of the composition. Preferably 2, 4 and 5%.
- the propenetrating agents should generally not dissolve the active agents at the percentage employed, should not cause exothermic reactions that damage the benzoyl peroxide, should help in the satisfactory dispersion of the active agents and should have anti-foaming properties.
- the propenetrating agents preferably used are compounds such as propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol and ethoxydiglycol.
- the particularly preferred propenetrating agent is propylene glycol.
- compositions according to the invention may also contain one or more wetting liquid surfactants in preferable concentrations ranging from 0.01 to 10% to more preferably ranging from 0.1 to 2%.
- the wetting ability is the tendency of a liquid to spread out over a surface.
- they are surfactants having a HLB (Hydrophillic Lipophilic Balance) of 7 to 12, or else non-ionic surfactants of polyoxyethylenated and/or polyoxypropylenated copolymer type.
- HLB Hydrophilic Lipophilic Balance
- non-ionic surfactants of polyoxyethylenated and/or polyoxypropylenated copolymer type should be liquid so as to easily be incorporated into the composition without it being necessary to heat them, the objective being, amongst other things, to obtain a low-temperature manufacturing method, which in no way limits the present invention.
- wetting agents preferably employed, without this list being limiting, are compounds of the family of poloxamers and more particularly Poloxamer 124 and/or Poloxamer 182.
- the particularly preferred wetting liquid surfactant is Poloxamer 124.
- composition may comprise, in addition, any additive commonly used in the cosmetic or pharmaceutical field, such as sequestrants, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants, dyes, common mineral or organic bases or acids, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA and skin soothing and protective agents such as allantoin.
- additives such as sequestrants, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants, dyes, common mineral or organic bases or acids, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA and skin soothing and protective agents such as allantoin.
- additives may be present in the composition in an amount of 0.001 to 20% by weight relative to the total weight of the composition.
- EDTA ethylenediamine tetracetic acid
- EDTA ethylenediamine tetracetic acid
- dihydroyethylglycine citric acid, tartric acid, or mixtures thereof.
- Exemplary are, as examples of preservatives, benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinylurea, parabens, or mixtures thereof.
- Exemplary are, as examples of humectants, glycerol and sorbitol.
- the present invention also features pharmaceutical or cosmetic compositions for topical application to the skin, integuments or mucous membranes, in the form of an aqueous gel, which comprise, formulated into a physiologically acceptable medium that is compatible with topical application to the skin, integuments or mucous membranes, an active phase comprising (expressed as percentage by weight):
- the aqueous phase of the composition according to the invention may comprise water, a floral water such as cornflower water, or a spring or natural mineral water, for example selected from among water from Vittel, waters from the Vichy basin, water from Uriage, water from la Roche Posay, water from la Bourboule, water from Enghien-les-Bains, water from Saint Gervais-les-Bains, water from Néris-les-Bains, water from Allevard-les-Bains, water from Digne, water from Maizines, water from Neyrac-les-Bains, water from Lons-le-Saunier, water from Bonnes, water from Rochefort, water from Saint Christau, water from Furnades and water from Tercis-les-Bains, water from Avène or water from Aix les Bains.
- a floral water such as cornflower water
- a spring or natural mineral water for example selected from among water from Vittel, waters from the Vichy basin, water from Uriage, water from la Roche Posay, water from la Bour
- Said aqueous phase may be present in an amount from 10 to 90% by weight relative to the total weight of the composition, preferably from 20 to 85% by weight.
- a preferred composition according to the invention comprises, in water:
- composition according to the invention comprises, in water:
- compositions according to the invention are conventional methods that can be carried out by one skilled in this art.
- the present invention also features the composition as described previously as medication.
- This invention also features the use of the composition as described previously in cosmetics or in dermatology.
- compositions of the invention are particularly suitable in the following therapeutic fields:
- a keratinization disorder having an inflammatory and/or immuno-allergic component and especially all forms of psoriasis whether they are cutaneous, mucous or ungula, and even psoriatic rheumatism, or else cutaneous atopy, such as eczema or respiratory atopy or else gingival hypertrophy; the compounds may also be used in certain inflammatory conditions that do not exhibit keratinization disorders, such as folliculitis;
- compositions according to the invention are particularly useful for the treatment, in a preventative and/or curative manner, of acne vulgaris.
- the present invention also features the production of a pharmaceutical preparation useful for preventing and/or treating dermatological conditions linked to cell differentiation and/or proliferation disorders and/or keratinization disorders, more particularly for the production of a pharmaceutical preparation useful to prevent and/or treat acne vulgaris.
- compositions according to the invention also find an application in body and hair hygiene.
- compositions according to the invention particularly find an application in the cosmetics field, in particular for treating acne-prone skin, for hair regrowth, for preventing hair loss, for combating the greasy appearance of the skin or hair, in protecting against the damaging effects of the sun or in treating physiologically greasy skin, or for preventing and/or combating light-induced or chronological aging.
- Macroscopic appearance White, smooth and shiny product Microscopic appearance: Good dispersion of both active agents.
- composition At the starting time (T0) the composition is considered to contain 100% of adapalene.
- composition At the starting time (T0) the composition is considered to contain 100% of benzoyl peroxide.
Abstract
Dermatological/cosmetic compositions contain, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system comprising at least two categories of compounds.
Description
- This application claims priority under 35 U.S.C. §119 of FR 0652967, filed Jul. 13, 2006 and U.S. Provisional Application No. 60/832,092, filed Jul. 21, 2006, and is a continuation/national phase of PCT/EP 2007/057091, filed Jul. 11, 2007 and designating the United States (published in the English language on Jan. 17, 2008 as WO 2008/006848 A1); each hereby expressly incorporated by reference in its entirety and each assigned to the assignee hereof.
- 1. Technical Field of the Invention
- The present invention relates to dermatological/cosmetic compositions comprising, formulated into a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and a gelling system which comprises at least two particular categories of compounds.
- 2. Description of Background and/or Related and/or Prior Art
- The administration of several classes of active principles is a therapeutic tool that is frequently employed, especially for treating dermatological disorders.
- Specifically, in the treatment of dermatitis it is known to administer corticosteroids such as, for example hydrocortisone, miconazole or betamethasone valerate, antihistamines (e.g., mizolastine) and/or keratolytic agents such as salicylic acid. Various anti-fungal agents such as allylamine derivatives, triazoles, anti-bacterial or anti-microbial agents such as, for example, antibiotics, quinolones and imidazoles are also conventionally combined in the treatment of dermatological diseases. Peroxides, D vitamins and retinoids are also described for the topical treatment of various pathologies associated with the skin or mucous membranes, in particular acne.
- The combination of several local treatments (antibiotics, retinoids, peroxides, zinc) is also employed in dermatology to increase the effectiveness of the active principles and to decrease their toxicity (Cunliffe W. J., J. Dermatol. Treat., 2000, 11 (Suppl. 2), 513-514).
- The multiple application of various dermatological products may be quite taxing and demanding for the patient.
- The advantage is therefore understood in seeking to obtain a novel treatment that is effective on dermatological conditions, that has a stable composition offering good cosmetic quality, allowing a single application and administration that is pleasant for the patient.
- However, the formulation of such a composition poses several problems.
- Firstly, the effectiveness of benzoyl peroxide is linked to its decomposition when it is placed in contact with skin. Indeed, it is the oxidizing properties of the free radicals produced during this decomposition that result in the desired effect. Thus, in order to maintain an optimal effectiveness of the benzoyl peroxide, it is important to prevent its decomposition before use, that is to say during storage.
- However, benzoyl peroxide is an unstable chemical compound which makes its formulation in finished products difficult.
- The solubility and stability of benzoyl peroxide have been studied by Chellquist et al. in ethanol, propylene glycol and various mixtures of polyethylene glycol 400 (PEG 400) and water (Chellquist E. M. and Gorman W. G., Pharm. Res., 1992, Vol. 9: 1341-1346). Benzoyl peroxide proved to be particularly soluble in PEG 400 and ethanol.
- This document furthermore specifies that the stability of benzoyl peroxide is strongly influenced by the chemical composition of the formulation and by the storage temperature.
- Benzoyl peroxide is extremely reactive and degrades in solution at low temperature due to the instability of its peroxide bond.
- The authors thus report that benzoyl peroxide in solution degrades more or less quickly in all the solvents studied, depending on the type of solvent and on its concentration.
- The degradation times of benzoyl peroxide in PEG 400 (0.5 mg/g), in ethanol and in propylene glycol are respectively 1.4, 29 and 53 days at 40° C. Such a degradation does not allow the preparation of a product useful for sale.
- Furthermore, it is known that benzoyl peroxide is more stable in water and propylene glycol when it is in suspension (i.e., in dispersed form), as it is not degraded after being kept for 90 days in these solvents.
- Thus, to limit the problem of rapid instability of benzoyl peroxide in solution, it has proved advantageous to formulate the benzoyl peroxide in dispersed form.
- Another difficulty to be overcome for preparing a composition comprising both benzoyl peroxide and a retinoid is that most retinoids are particularly sensitive to natural oxidation, to visible light and to ultraviolet light, and since benzoyl peroxide is a strong oxidizer the chemical compatibility of these compounds in one and the same formulation poses numerous stability problems from a physical and chemical viewpoint.
- A study on the stability of two retinoids was carried out by combining two commercial products, one containing a retinoid (tretinoin or adapalene) and the second based on benzoyl peroxide (B. Martin et al, Br. J. Dermatol., (1998) 139, (suppl. 52), 8-11).
- The presence of the formulation based on benzoyl peroxide causes a very rapid degradation of the oxidation-sensitive retinoids: it is calculated that 50% of the tretinoin is degraded in 2 hours and 95% in 24 hours. In the composition in which the retinoid is adapalene, no degradation of the adapalene was measured over 24 hours.
- This study confirms that the benzoyl peroxide is degraded and degrades the oxidation-sensitive retinoids over time by gradually releasing benzoic acid into the initial products.
- On the other hand, no indication was given regarding the physical stability of the two compositions brought together, nor on the therapeutic activity likely to be obtained at the end by combining the two active principles in the same composition.
- Nothing would prompt these two active agents to be combined in order to obtain a stable gel-type composition, given that it was commonly known that the presence of benzoyl peroxide chemically and physically destabilized this type of composition.
- However, it is clear that the too rapid degradation of benzoyl peroxide and the chemical degradation of the retinoids is undesirable insofar as it impairs the effectiveness of the composition containing them.
- Furthermore, a finished product, in particular when it is a pharmaceutical or cosmetic composition, must maintain, throughout its shelf life, precise physicochemical criteria that make it possible to guarantee its pharmaceutical or cosmetic quality respectively. Among these criteria, it is necessary that the rheological properties be retained. They define the behavior and texture of the composition during application, but also the release properties of the active principle [1998 SFSTP Commission Report] and the homogeneity of the product when the active principles are present therein in the dispersed state.
- In particular, the formulation of benzoyl peroxide and a retinoid in gel form is advantageous for topical treatments, such as those of acne, as it especially avoids maintaining a greasy feel on the skin.
- Another difficulty to be overcome for preparing a composition especially comprising benzoyl peroxide, when it is in gel form, is that the gelling agents are destabilized by the benzoic acid released during the degradation of benzoyl peroxide.
- Indeed, the most commonly used thickening agents for formulating these compositions with benzoyl peroxide are acrylic acid polymers (Carbomer).
- However, the use of carbomers in aqueous gel-type compositions does not give good results in terms of chemical stability of benzoyl peroxide and in terms of rheological stability. As described by Bollinger (Bollinger, Journal of Pharmaceutical Science, 1977, Vol. 5), a loss of 5 to 20% benzoyl peroxide has been observed at the end of 2 months at 40° C. depending on the carbomer neutralizer used. Furthermore, the release of benzoic acid causes the depolymerization of the carbomers, causing a drop in viscosity which may result in phase separation.
- This instability of benzoyl peroxide gels impairs their effectiveness and their cosmetic quality.
- Therefore, the need remains to provide a physically stable gelled composition comprising benzoyl peroxide and a retinoid. However, nothing among the range of therapies proposed to one skilled in this art would suggest the combination, in the same composition, of benzoyl peroxide and a retinoid and several different gelling agents.
- Nonetheless, novel compositions have now surprisingly been developed satisfying this need, which comprise dispersed, free or encapsulated benzoyl peroxide, at least one retinoid and a gelling system comprising at least two categories of compounds, such compositions having good physical stability, that is to say not having a drop in viscosity over time and at ambient temperature (from 20 to 30° C.), and maintaining good chemical stability of the two active agents (benzoyl peroxide and retinoid). In particular, no degradation of the active agents is observed over time and/or at ambient temperature.
- The present invention therefore features compositions, especially pharmaceutical compositions, comprising, formulated into a physiologically acceptable medium:
- at least one retinoid;
- benzoyl peroxide; and
- a gelling system which comprises at least two categories of compounds,
- said categories of compounds being selected from among silicates, cellulose gelling agents and polysaccharide gums, with the proviso that when at least two gelling agents are selected from among aluminum/magnesium silicate, xanthan gum and hydroxypropyl cellulose, the gelling system is composed of these two gelling agents, or comprises at least one gelling agent different from these three compounds.
- The term “gelling system” means a combination of gelling compounds that gives the composition a sufficient viscosity to maintain the retinoid and the benzoyl peroxide in suspension, even under the influence, in particular, of a pH variation due to the release of benzoic acid by the benzoyl peroxide.
- The term “physiologically acceptable medium” means a medium that is compatible with the skin, the mucous membranes and/or the integuments.
- The compositions according to the invention are preferably in the form of an aqueous gel, which is particularly well suited to the target pathologies.
- A gel is a system comprising at least one phase (in general one or two phases), which is thermodynamically stable, resulting from the coagulation of a colloidal solution into a three-dimensional network. More specifically, an aqueous gel corresponds to a composition containing, in an aqueous phase, a visco-elastic mass formed from colloidal suspensions.
- More specifically, the gelling system comprises at least two categories of compounds, naturally different and distinct, said categories of compounds being selected from among silicates, cellulose gelling agents and polysaccharide gums.
- The term “silicate” is understood in particular to mean clay derivatives, more specifically aluminum and magnesium silicates. The silicates are generally obtained from mineral clays having a crystalline lattice that are dissolved and purified in water to optimize the purity and effectiveness of the product. These compounds are especially marketed by R. T. Vanderbilt under the trademark VEEGUM® (for example: VEEGUM® HV or VEEGUM® K).
- The amount of silicate may vary over a wide range and depends in particular on the desired viscosity and on the other gelling agent and/or agents present in the composition. To provide an order of magnitude, the silicate may be present in the composition according to the invention in concentrations from 0.1 to 10%, preferably ranging from 0.1 to 5% by weight relative to the total weight of the composition. Advantageously, the amount is from 0.5 to 2%, even more preferably from 0.8 to 1.8%, such as for example 1%, relative to the total weight of the composition.
- The term “cellulose gelling agent” means water-soluble polymers derived from cellulose. These polymers form water-soluble ethers (semi-synthetic cellulose) originating from viscous solutions after dissolving in an aqueous solution. Among the cellulose polymers, especially exemplary are methyl cellulose, ethyl cellulose, hydroxypropylmethyl cellulose, hydroxyethyl cellulose, hydroxylpropyl cellulose, carboxymethyl cellulose and hydroxymethyl cellulose. Preferably hydroxypropylmethyl cellulose or hydroxyethyl cellulose are used. These compounds are especially marketed by Dow Chemical under the trademark METHOCEL® (for example: METHOCEL® E4M) or by Hercules under the trademark NATROSOL® (for example: NATROSOL® 250 HHX).
- The amount of cellulose gelling agent may vary over a wide range and in particular depends on the desired viscosity and on the other gelling agent and/or agents present in the composition. To provide an order of magnitude, the cellulose-based gelling agent may be present in the composition according to the invention in amounts from 0.1 to 10%, preferably ranging from 0.1 to 5% by weight relative to the total weight of composition. Advantageously, the amount is from 0.5 to 2%, such as for example 0.5%, 1%, 1.5% or 2% relative to the total weight of the composition.
- Polysaccharide gums are complex mixtures of several high-molecular weight polysaccharides obtained by exudation from certain plants. Among the different types of polysaccharide gums, non-limiting examples thereof are gum Arabic, gum tragacanth and xanthan gum, amongst another marketed by CP Kelco under the trademark XANTURAL® (for example: XANTURAL® 180).
- The amount of polysaccharide gum may vary over a wide range and depends in particular on the desired viscosity and on the other gelling agent and/or agents present in the composition. To provide an order of magnitude, the polysaccharide gum may be present in the composition according to the invention in amounts from 0.01 to 5%, preferably ranging from 0.05 to 2% by weight relative to the total weight of the composition. Advantageously, the amount is from 0.1 to 0.8% such as, for example, 0.1%, 0.2% or 0.5% relative to the total weight of the composition.
- The gelling system may comprise two categories of compounds or three categories of compounds, said categories of compounds being selected from among silicates, cellulose gelling agents and polysaccharide gums.
- According to one particular embodiment, the gelling system comprising two categories of compounds comprises at least one cellulose gelling agent (in particular hydroxypropylmethyl cellulose or hydroxyethyl cellulose) in combination with a silicate or a xanthan gum, taking into account the condition indicated above.
- According to another particular embodiment, the gelling system comprising two categories of compounds comprises at least one silicate, in combination with a polysaccharide gum, taking into account the condition indicated above.
- According to another particular embodiment, the gelling system comprising two categories of compounds comprises at least one polysaccharide gum, in combination with a cellulose gelling agent (in particular hydroxypropylmethyl cellulose or hydroxyethyl cellulose), taking into account the condition indicated above.
- The gelling system may also comprise at least one silicate, at least one cellulose gelling agent and at least one polysaccharide gum, taking into account the condition indicated above.
- Among the gelling systems having three categories of compounds, especially exemplary is the combination of polysaccharide gum, silicate and a cellulose gelling agent, taking into account the condition indicated above.
- According to variants of the invention, the subject compositions may, in addition, comprise an additional gelling agent which may especially be selected from among mixtures of polyacrylamides such as the sodium acryloyidimethyltaurate copolymer/isohexadecane/polysorbate 80 mixture marketed under the trademark SIMULGEL 600 by Seppic, the polyacrylamide/C13-14 isoparaffin/laureth-7 mixture such as, for example, that marketed under the trademark SEPIGEL 305 by Seppic, the family of acrylic polymers coupled to hydrophobic chains such as the PEG-150/decyl/SMDI copolymer marketed under the trademark ACULYN 44 (polycondensate comprising at least, as components, a polyethylene glycol having 150 or 180 moles of ethylene oxide, decyl alcohol and methylenebis(4-cyclohexylisocyanate) (SMDI), at 35% by weight in a mixture of propylene glycol (39%) and water (26%)), the family of modified starches such as the modified potato starch marketed under the trademark STRUCTURE SOLANACE or else mixtures thereof.
- The compositions according to the invention contain at least one retinoid. The term “retinoid” means any compound that binds to RAR and/or RXR receptors.
- Preferably, the retinoid is a compound selected from among the family of benzonaphthalenic retinoids as described in EP 0 199 636, and especially:
- 6-(3-methylphenyl)-2-naphthoic acid and its methyl ester;
- 6-(4-tert-butylphenyl)-2-naphthoic acid and its methyl ester;
- 6-(3-tert-butylphenyl)-2-naphthoic acid and its methyl ester;
- 6-(3,4-dimethoxyphenyl)-2-naphthoic acid and its methyl ester;
- 6-(p-(1-adamantylthio)phenyl)-2-naphthoic acid and its methyl ester;
- 6-(3-(1-adamantyl)-4-methoxyphenyl)-2-naphthoic acid (adapalene) and its methyl ester;
- the methyl ester of 6-[3-(1-adamantyl)-4-tert-butyldimethylsilyloxyphenyl)-2-naphthoic acid;
- the methyl ester of 6-[3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthoic acid;
- 6-[3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthoic acid;
- the methyl ester of 6-[3-(1-adamantyl)-4-decyloxyphenyl)-2-naphthoic acid;
- 6-[3-(1-adamantyl)-4-decyloxyphenyl)-2-naphthoic acid;
- the methyl ester of 6-[3-(1-adamantyl)-4-hexyloxyphenyl)-2-naphthoic acid;
- 6-[3-(1-adamantyl)-4-hexyloxyphenyl)-2-naphthoic acid;
- the methyl ester of 6-[3-(1-adamantyl)-4-methoxyphenyl)-4-acetoxy-1-methyl-2-naphthoic acid;
- 6-[3-(1-adamantyl)-4-methoxyphenyl)-4-hydroxy-1-methyl-2-naphthoic acid;
- the methyl ester of 6-[3-(1-adamantyl)-4-methoxyphenyl)-4-hydroxy-1-methyl-2-naphthoic acid;
- the methyl ester of 6-[3-(1-adamantyl)-4-methoxyphenyl)-1-methyl-2-naphthoic acid;
- 6-[3-(1-adamantyl)-4-methoxyphenyl)-1-methyl-2-naphthoic acid;
- 6-[3-(1-adamantyl)-4-methoxyphenyl)-2-naphthalene methanol;
- the ethylamide of 6-[3-(1-adamantyl)-4-methoxyphenyl)-2-naphthoic acid;
- the morpholide of 6-[3-(1-adamantyl)-4-methoxyphenyl)-2-naphthoic acid;
- the methyl ester of 6-[3-tert-butyl-4-methoxyphenyl)-2-naphthoic acid;
- 6-[3-tert-butyl-4-methoxyphenyl)-2-naphthoic acid;
- the methyl ester of 6-[3-(1,1-dimethyldecyl)-4-methoxyphenyl)-2-naphthoic acid;
- 6-[3-(1,1-dimethyldecyl)-4-methoxyphenyl)-2-naphthoic acid.
- In particular, adapalene and also its salts will be preferred.
- The term “adapalene salts” means the salt formed with a pharmaceutically acceptable base, especially mineral bases such as sodium hydroxide, potassium hydroxide and ammonia or organic bases such as lysine, arginine or N-methylglucamine.
- The term “adapalene salts” is also understood to mean the salts formed with fatty amines such as dioctylamine and stearylamine.
- Other retinoids may be selected from among those described in the following patents or patent applications: U.S. Pat. Nos. 4,666,941, 4,581,380, EP 0 210 929, EP 0 232 199, EP 0 260 162, EP 0 292 348, EP 0 325 540, EP 0 359 621, EP 0 409 728, EP 0 409 740, EP 0 552 282, EP 0 584 191, EP0 514 264, EP0 514 269, EP0 661 260, EP0 661 258, EP 0 658 553, EP 0 679 628, EP 0 679 631, EP 0 679 630, EP 0 708 100, EP 0 709 382, EP 0 722 928, EP 0 728 739, EP 0 732 328, EP 0 740 937, EP 0 776 885, EP 0 776 881, EP 0 823 903, EP 0 832 057, EP 0 832 081, EP 0 816 352, EP 0 826 657, EP 0 874 626, EP 0 934 295, EP 0 915 823, EP 0 882 033, EP 0 850 909, EP 0 879 814, EP 0 952 974, EP 0 905 118, EP 0 947 496, WO 98/56783, WO 99/10322, WO 99/50239, WO 99/65872.
- Of course, the amount of the two active agents, benzoyl peroxide and retinoid, in the composition according to the invention, will depend on the combination selected and therefore particularly on the retinoid in question and on the quality of the desired treatment.
- The preferred retinoid concentrations are from 0.0001 to 20% by weight relative to the total weight of the composition.
- Benzoyl peroxide could also be used in the free form or else in an encapsulated form in a form adsorbed on, or absorbed in, any porous support.
- It could for example be benzoyl peroxide encapsulated in a polymer system made of porous microspheres, such as for example microsponges marketed under the trademark MICROSPONGES P009A Benzoyl Peroxide by Cardinal Healthcare.
- To provide an order of magnitude, the compositions according to the invention advantageously comprise from 0.0001 to 20% by weight of benzoyl peroxide and from 0.0001 to 20% by weight of retinoid relative to the total weight of the composition, and preferably, respectively, from 0.025 to 10% by weight of benzoyl peroxide and from 0.001 to 10% by weight of retinoid relative to the total weight of the composition.
- For example, in compositions for treating acne, benzoyl peroxide is preferably present at concentrations ranging from 2 to 10% by weight and more particularly from 2.5 to 5% by weight relative to the total weight of the composition. Retinoid is itself present in this type of composition at concentrations generally ranging from 0.05 to 1% by weight relative to the total weight of the composition.
- Advantageously, the particle size of the retinoid and of the benzoyl peroxide is such that at least 80% by number of particles, and preferably at least 90% by number of particles, have a diameter of less than 25 μm and at least 99% by number of particles have a diameter of less than 100 μm.
- According to the invention, advantageously, the gel containing the benzoyl peroxide and a retinoid comprises at least water and may also comprise a propenetrating agent and/or a wetting liquid surfactant.
- The compositions of the invention may contain one or more propenetrating agents in preferable concentrations ranging from 0.01 to 20% to more preferably ranging from 2 to 6% by weight relative to the total weight of the composition. Preferably 2, 4 and 5%.
- The propenetrating agents should generally not dissolve the active agents at the percentage employed, should not cause exothermic reactions that damage the benzoyl peroxide, should help in the satisfactory dispersion of the active agents and should have anti-foaming properties. Among the propenetrating agents preferably used, without this list being limiting, are compounds such as propylene glycol, dipropylene glycol, propylene glycol dipelargonate, lauroglycol and ethoxydiglycol.
- The particularly preferred propenetrating agent is propylene glycol.
- Advantageously, the compositions according to the invention may also contain one or more wetting liquid surfactants in preferable concentrations ranging from 0.01 to 10% to more preferably ranging from 0.1 to 2%. The wetting ability is the tendency of a liquid to spread out over a surface.
- Preferably, they are surfactants having a HLB (Hydrophillic Lipophilic Balance) of 7 to 12, or else non-ionic surfactants of polyoxyethylenated and/or polyoxypropylenated copolymer type. They should be liquid so as to easily be incorporated into the composition without it being necessary to heat them, the objective being, amongst other things, to obtain a low-temperature manufacturing method, which in no way limits the present invention.
- Among the wetting agents preferably employed, without this list being limiting, are compounds of the family of poloxamers and more particularly Poloxamer 124 and/or Poloxamer 182.
- The particularly preferred wetting liquid surfactant is Poloxamer 124.
- The composition may comprise, in addition, any additive commonly used in the cosmetic or pharmaceutical field, such as sequestrants, antioxidants, sunscreens, preservatives, fillers, electrolytes, humectants, dyes, common mineral or organic bases or acids, fragrances, essential oils, cosmetic active agents, moisturizers, vitamins, essential fatty acids, sphingolipids, self-tanning compounds such as DHA and skin soothing and protective agents such as allantoin.
- Of course, one skilled in this art will take care to select this or these optional additional compounds, and/or their amount, so that the advantageous properties of the composition according to the invention are not, or are not substantially, adversely affected.
- These additives may be present in the composition in an amount of 0.001 to 20% by weight relative to the total weight of the composition.
- Exemplary are, as examples of sequestering agents, ethylenediamine tetracetic acid (EDTA), and also derivatives or salts thereof, dihydroyethylglycine, citric acid, tartric acid, or mixtures thereof.
- Exemplary are, as examples of preservatives, benzalkonium chloride, phenoxyethanol, benzyl alcohol, diazolidinylurea, parabens, or mixtures thereof.
- Exemplary are, as examples of humectants, glycerol and sorbitol.
- In particular, the present invention also features pharmaceutical or cosmetic compositions for topical application to the skin, integuments or mucous membranes, in the form of an aqueous gel, which comprise, formulated into a physiologically acceptable medium that is compatible with topical application to the skin, integuments or mucous membranes, an active phase comprising (expressed as percentage by weight):
- 20 to 90% of water;
- 0 to 10%, preferably 0 to 2%, especially 0 to 0.5% of wetting liquid surfactant;
- 0 to 20%, preferably 0 to 10%, especially 2 to 5% of propenetrating agent;
- 0.0001 to 20%, preferably 0.025 to 10% of benzoyl peroxide;
- 0.0001 to 20%, preferably 0.001 to 10% of retinoid; and
- 0.11 to 25% of a gelling system as described above.
- The aqueous phase of the composition according to the invention may comprise water, a floral water such as cornflower water, or a spring or natural mineral water, for example selected from among water from Vittel, waters from the Vichy basin, water from Uriage, water from la Roche Posay, water from la Bourboule, water from Enghien-les-Bains, water from Saint Gervais-les-Bains, water from Néris-les-Bains, water from Allevard-les-Bains, water from Digne, water from Maizières, water from Neyrac-les-Bains, water from Lons-le-Saunier, water from Bonnes, water from Rochefort, water from Saint Christau, water from Furnades and water from Tercis-les-Bains, water from Avène or water from Aix les Bains.
- Said aqueous phase may be present in an amount from 10 to 90% by weight relative to the total weight of the composition, preferably from 20 to 85% by weight.
- A preferred composition according to the invention comprises, in water:
- 2.5% of benzoyl peroxide;
- 0.1% of adapalene;
- 0.1% of disodium EDTA;
- 2%-4% of glycerol;
- 2%-6%; (preferably 2%, 4% or 5%) of propylene glycol
- 0%-0.05% of sodium docusate;
- 2%-4% of a gelling system as described above; and
- 0.2%-0.5% of Poloxamer 124.
- A particularly preferred composition according to the invention comprises, in water:
-
Adapalene 0.1% Benzoyl peroxide qs 2.5% BPO Propylene glycol 4% Poloxamer 124 0.1% Aluminum/magnesium silicate 2% Hydroxyethyl cellulose 1.5% Xanthan gum 0.5% Glycerol 2% Sodium docusate 0.05% - The methods for preparing the compositions according to the invention are conventional methods that can be carried out by one skilled in this art.
- The present invention also features the composition as described previously as medication.
- This invention also features the use of the composition as described previously in cosmetics or in dermatology.
- On account of the keratolytic, bactericidal and anti-inflammatory activity of benzoyl peroxide and the pronounced activity of retinoids in the fields of cell differentiation and proliferation, the compositions of the invention are particularly suitable in the following therapeutic fields:
- 1) for treating dermatological conditions or afflictions associated with a keratinization disorder relating to differentiation and proliferation, especially for treating acne vulgaris and comedonal, polymorphous and rosacea acnes, nodulocystic acne and acne conglobara, senile acne, secondary acne such as solar, drug or occupational acne and hidradenitis suppurativa;
- 2) for treating other types of keratinization disorders, especially ichthyosis, ichthyosiform states, Darrier's disease, palmoplantar keratoderma, leukoplakia or leucoplakiform states, and cutaneous or mucous (buccal) lichen;
- 3) for treating other dermatological conditions or afflictions associated with a keratinization disorder having an inflammatory and/or immuno-allergic component and especially all forms of psoriasis whether they are cutaneous, mucous or ungula, and even psoriatic rheumatism, or else cutaneous atopy, such as eczema or respiratory atopy or else gingival hypertrophy; the compounds may also be used in certain inflammatory conditions that do not exhibit keratinization disorders, such as folliculitis;
- 4) for treating all dermal or epidermal proliferations, whether benign or malignant, whether or not they are of viral origin, such as verrucas, plane warts, molluscum contagiosum and epidermodysplasia verruciformis, oral or floride papillomatoses and proliferations which may be induced by ultraviolet light especially in the case of actinic keratoses;
- 5) for repairing or combating skin aging, whether light-induced or chronological, or for reducing pigmentation, or any pathologies associated with chronological and actinic aging;
- 6) for treating wound-healing disorders or skin ulcers in a preventative or curative manner, for preventing or repairing striae atrophicae, or else for promoting wound healing;
- 7) for combating sebaceous gland disorders such as hyperseborrhea of acne or simple seborrhea;
- 8) in treating any skin condition or affliction of fungal origin, such as tinea pedis and tinea versicolor;
- 9) in the treatment of dermatological conditions or afflictions having an immunological component;
- 10) in the treatment of skin disorders due to exposure to UV radiation; and
- 11) in the treatment of dermatological conditions or afflictions associated with an inflammation or infection of the tissues surrounding the hair follicle, especially due to a microbial colonization or infection, especially impetigo, seborrheic dermatitis, folliculitis, sycosis barbae or those involving any other bacterial or fungal agent.
- The compositions according to the invention are particularly useful for the treatment, in a preventative and/or curative manner, of acne vulgaris.
- The present invention also features the production of a pharmaceutical preparation useful for preventing and/or treating dermatological conditions linked to cell differentiation and/or proliferation disorders and/or keratinization disorders, more particularly for the production of a pharmaceutical preparation useful to prevent and/or treat acne vulgaris.
- The compositions according to the invention also find an application in body and hair hygiene.
- The compositions according to the invention particularly find an application in the cosmetics field, in particular for treating acne-prone skin, for hair regrowth, for preventing hair loss, for combating the greasy appearance of the skin or hair, in protecting against the damaging effects of the sun or in treating physiologically greasy skin, or for preventing and/or combating light-induced or chronological aging.
- In order to further illustrate the present invention and the advantages thereof, the following specific examples are given, it being understood that same are intended only as illustrative and in nowise limitative. In said examples to follow, all parts and percentages are given by weight, unless otherwise indicated.
- a) Silicate/Gum Tragacanth:
-
Water qs 100% Adapalene 0.1% Benzoyl peroxide qs 2.5% BPO Propylene glycol 2% Poloxamer 124 0.2% Disodium EDTA 0.1% Silicate (Veegum K) 2% Gum tragacanth 0.5% Glycerol 2% Sodium docusate 0.05% - b) Xanthan Gum/Cellulose (Hydroxyethyl Cellulose):
-
Water qs 100% Adapalene 0.1% Benzoyl peroxide qs 2.5% BPO Propylene glycol 4% Poloxamer 124 0.2% Disodium EDTA 0.1% Hydroxyethyl cellulose (Natrosol HHX) 2% Xanthan gum (Xantural 18) 0.2% Glycerol 4% - c) Cellulose/Silicate:
-
Water qs 100% Adapalene 0.1% Benzoyl peroxide qs 2.5% BPO Dipropylene glycol 4% Poloxamer 124 0.2% Disodium EDTA 0.1% Hydroxyethyl cellulose (Natrosol HHX) 2% Silicate (Veegum HV) 1% Glycerol 4% Sodium docusate 0.05% - a) Silicate/Cellulose/Xanthan Gum:
-
Water qs 100% Adapalene 0.1% Benzoyl peroxide qs 2.5% BPO Propylene glycol 4% Poloxamer 124 0.2% Disodium EDTA 0.1% Veegum K 2% Hydroxyethyl cellulose (Natrosol HHX) 1.5% Xanthan gum (Xantural 180) 0.5% Glycerol microsponges 4% Glycerol 2% Sodium docusate 0.05% - Specifications at T0:
- Macroscopic appearance: White, smooth and shiny product
Microscopic appearance: Good dispersion of both active agents. - Physical Stability:
-
Stability Time conditions T 1 month T 2 months T 3 months TA Conforms to Conforms to Conforms to specifications specifications specifications 40° C. Conforms to Conforms to Conforms to specifications specifications specifications Slightly yellowing of Slightly yellowing the product of the product - Chemical Stability:
- Adapalene:
- Assay of the active by internal calibration in HPLC.
- At the starting time (T0) the composition is considered to contain 100% of adapalene. Concentration of adapalene measured in % relative to T0:
-
Stability Time conditions T 0 T 1 month T 2 months T 3 months AT NR NR NR 97.7% 40° C. NR NR NR - Benzoyl Peroxide:
- Assay of the active by internal calibration in HPLC.
- At the starting time (T0) the composition is considered to contain 100% of benzoyl peroxide. Concentration of benzoyl peroxide measured in % relative to T0:
-
Stability Time conditions T 0 T 1 month T 2 months T 3 months AT 99.2 NR NR 94.8 40° C. 96.3 81.6% 88.7 - b) Silicate/Cellulose/Xanthan Gum:
-
Water qs 100% Adapalene 0.1% Benzoyl peroxide qs 2.5% BPO Propylene glycol 5% Poloxamer 124 0.5% Disodium EDTA 0.1% Veegum K 2% Hydroxyethyl cellulose (Methocel E4M) 0.5% Xanthan gum (Xantural 180) 0.1% Glycerol 4% Sodium docusate 0.05% - c) Silicate/Cellulose/Gum Arabic:
-
Water qs 100% Adapalene 0.1% Benzoyl peroxide qs 2.5% BPO Propylene glycol 5% Poloxamer 124 0.5% Disodium EDTA 0.1% Veegum K 2% Carboxymethyl cellulose 0.5% Gum arabic 0.1% Glycerol 4% Sodium docusate 0.05% - Each patent, patent application, publication, text and literature article/report cited or indicated herein is hereby expressly incorporated by reference in its entirety.
- While the invention has been described in terms of various specific and preferred embodiments, the skilled artisan will appreciate that various modifications, substitutions, omissions, and changes may be made without departing from the spirit thereof. Accordingly, it is intended that the scope of the present invention be limited solely by the scope of the following claims, including equivalents thereof.
Claims (24)
1. A dermatological/cosmetic composition comprising:
at least one retinoid;
benzoyl peroxide; and
a gelling system which comprises at least two categories of compounds,
said categories of compounds being selected from among silicates, cellulose gelling agents and polysaccharide gums, with the proviso that when at least two gelling agents are selected from among aluminum/magnesium silicate, xanthan gum and hydroxypropyl cellulose, the gelling system is composed of these two gelling agents, or comprises at least one gelling agent different from these three compounds.
2. The dermatological/cosmetic composition as defined by claim 1 , comprising magnesium and aluminum silicates.
3. The dermatological/cosmetic composition as defined by claim 1 , comprising an amount of silicate ranging from 0.1 to 10% by weight relative to the total weight of the composition.
4. The dermatological/cosmetic composition as defined by claim 1 , comprising cellulose gelling agents selected from among methyl cellulose, ethyl cellulose, hydroxypropyl methyl cellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxymethyl cellulose and hydroxypropyl cellulose.
5. The dermatological/cosmetic composition as defined by claim 1 , comprising an amount of cellulose gelling agent ranging from 0.1 to 10% by weight relative to the total weight of the composition.
6. The dermatological/cosmetic composition as defined by claim 1 , comprising an amount of polysaccharide gum ranging from 0.01 to 5% by weight relative to the total weight of the composition.
7. The dermatological/cosmetic composition as defined by claim 1 , wherein the gelling system comprises at least one cellulose gelling agent in combination with a silicate.
8. The dermatological/cosmetic composition as defined by claim 1 , wherein the gelling system comprises at least one silicate in combination with a polysaccharide gum.
9. The dermatological/cosmetic composition as defined by claim 1 , wherein the gelling system comprises at least one polysaccharide gum in combination with a cellulose gelling agent.
10. The dermatological/cosmetic composition as defined by claim 1 , wherein the gelling system comprises at least one silicate, at least one cellulose gelling agent and at least one polysaccharide gum.
11. The dermatological/cosmetic composition as defined by claim 1 , comprising from 0.0001 to 20% of retinoid.
12. The dermatological/cosmetic composition as defined by claim 1 , wherein the retinoid comprises adapalene.
13. The dermatological/cosmetic composition as defined by claim 1 , comprising from 0.0001 to 20% of benzoyl peroxide.
14. The dermatological/cosmetic composition as defined by claim 1 , wherein the benzoyl peroxide is encapsulated or free.
15. The dermatological/cosmetic composition as defined by claim 1 , comprising a propenetrating agent.
16. The dermatological/cosmetic composition as defined by claim 15 , said propenetrating agent comprising propylene glycol.
17. The dermatological/cosmetic composition as defined by claim 1 , comprising a wetting liquid surfactant.
18. The dermatological/cosmetic composition as defined by claim 17 , said wetting liquid surfactant comprising a poloxamer.
19. The dermatological/cosmetic composition as defined by claim 1 , which comprises, in water:
2.5% of benzoyl peroxide;
0.1% of adapalene;
0.1% of disodium EDTA;
2%-4% of glycerol;
2%-6% of propylene glycol;
0%-0.05% of sodium docusate;
2%-4% of a gelling system; and
0.2%-0.5% of Poloxamer 124.
20. The dermatological/cosmetic composition as defined by claim 1 , which comprises, in water:
21. A medication comprising the dermatological/cosmetic composition as defined by claim 1 .
22. A regime or regimen to prevent and/or treat a dermatological condition linked to cell differentiation and/or proliferation disorders and/or keratinization disorders, comprising administering to an individual in need of such treatment, a thus effective amount of the dermatological/cosmetic composition as defined by claim 1 .
23. A regime or regimen to prevent and/or treat acne vulgaris, comprising administering to an individual in need of such treatment, a thus effective amount of the dermatological/cosmetic composition as defined by claim 1 .
24. A regime or regimen for treating acne-prone skin, for hair regrowth, for preventing hair loss, for combating the greasy appearance of the skin or hair, for protecting against the damaging effects of the sun or for treating physiologically greasy skin, or for preventing and/or combating light-induced or chronological aging, comprising administering to an individual in need of such treatment, a thus effective amount of the dermatological/cosmetic composition as defined by claim 1 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/110,814 US9060948B2 (en) | 2006-07-13 | 2011-05-18 | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0652967A FR2903604B1 (en) | 2006-07-13 | 2006-07-13 | COMPOSITION COMPRISING A RETINOID AND BENZOYL PEROXIDE |
FR0652967 | 2006-07-13 | ||
PCT/EP2007/057091 WO2008006848A1 (en) | 2006-07-13 | 2007-07-11 | Composition comprising a retinoid and benzoyl peroxide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2007/057091 Continuation WO2008006848A1 (en) | 2006-07-13 | 2007-07-11 | Composition comprising a retinoid and benzoyl peroxide |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/110,814 Continuation US9060948B2 (en) | 2006-07-13 | 2011-05-18 | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100022642A1 true US20100022642A1 (en) | 2010-01-28 |
Family
ID=37453157
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/318,938 Abandoned US20100022642A1 (en) | 2006-07-13 | 2009-01-13 | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide |
US13/110,814 Active US9060948B2 (en) | 2006-07-13 | 2011-05-18 | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/110,814 Active US9060948B2 (en) | 2006-07-13 | 2011-05-18 | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide |
Country Status (3)
Country | Link |
---|---|
US (2) | US20100022642A1 (en) |
BR (1) | BRPI0713221B8 (en) |
FR (1) | FR2903604B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080176954A1 (en) * | 2001-12-21 | 2008-07-24 | Galderma Research & Development, S.N.C. | Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
WO2013124820A1 (en) | 2012-02-21 | 2013-08-29 | Ranbaxy Laboratories Limited | Composition comprising a retinoid and benzoyl peroxide |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4355028A (en) * | 1978-04-04 | 1982-10-19 | Westwood Pharmaceuticals, Inc. | Composition for treating acne vulgaris |
US20030170196A1 (en) * | 2001-12-21 | 2003-09-11 | Sandrine Orsoni | Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ194326A (en) * | 1979-07-25 | 1982-05-31 | Dermik Lab Inc | Stable aqueous benzoyl peroxide compositions and therapeutic compositions |
IT1210608B (en) * | 1980-12-08 | 1989-09-14 | Rorer Int Overseas | COMPOSITION FOR TOPICAL ACNE TREATMENT |
LU84485A1 (en) * | 1982-11-22 | 1984-06-13 | Oreal | NOVEL ANTI-ACNE COMPOSITION BASED ON BENZOYL PEROXIDE AND AT LEAST ONE OTHER ACTIVE INGREDIENT |
FR2687312A1 (en) * | 1992-02-14 | 1993-08-20 | Denner Alfred | Compositions for application to the skin intended for the treatment and prevention of wrinkles and shadows under the eyes. |
IL105217A0 (en) * | 1992-04-09 | 1993-07-08 | Allergan Inc | Method and composition for treating acne |
FR2787322B1 (en) * | 1998-12-18 | 2002-10-18 | Galderma Res & Dev | OIL-IN-WATER EMULSION COMPRISING A MICRONIZED ACTIVE AGENT AND AN APPROPRIATE EMULSION SYSTEM |
FR2833841B1 (en) * | 2001-12-21 | 2005-07-22 | Galderma Res & Dev | GEL COMPRISING AT LEAST ONE RETINOID AND BENZOYL PEROXIDE |
US9107844B2 (en) * | 2006-02-03 | 2015-08-18 | Stiefel Laboratories Inc. | Topical skin treating compositions |
FR2909000B1 (en) * | 2006-11-28 | 2009-02-06 | Galderma Res & Dev S N C Snc | COMPOSITIONS COMPRISING BENZOYL PEROXIDE, AT LEAST ONE NAPHTHOIC ACID DERIVATIVE AND AT LEAST ONE POLYURETHANE POLYMER COMPOUND OR DERIVATIVES THEREOF, AND USES THEREOF. |
-
2006
- 2006-07-13 FR FR0652967A patent/FR2903604B1/en not_active Expired - Fee Related
-
2007
- 2007-07-11 BR BRPI0713221A patent/BRPI0713221B8/en active IP Right Grant
-
2009
- 2009-01-13 US US12/318,938 patent/US20100022642A1/en not_active Abandoned
-
2011
- 2011-05-18 US US13/110,814 patent/US9060948B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4355028A (en) * | 1978-04-04 | 1982-10-19 | Westwood Pharmaceuticals, Inc. | Composition for treating acne vulgaris |
US20030170196A1 (en) * | 2001-12-21 | 2003-09-11 | Sandrine Orsoni | Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
US20080181963A1 (en) * | 2001-12-21 | 2008-07-31 | Galderma Research & Development, S.N.C. | Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080176954A1 (en) * | 2001-12-21 | 2008-07-24 | Galderma Research & Development, S.N.C. | Dermatological/cosmetic gels comprising at least one retinoid and benzoyl peroxide |
US8936800B2 (en) | 2001-12-21 | 2015-01-20 | Galderma Research & Development | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
US9814690B2 (en) | 2001-12-21 | 2017-11-14 | Galderma Research & Development | Gel composition for treatment of common acne comprising a combination of benzoyl peroxide and adapalene and/or adapalene salt |
WO2013124820A1 (en) | 2012-02-21 | 2013-08-29 | Ranbaxy Laboratories Limited | Composition comprising a retinoid and benzoyl peroxide |
Also Published As
Publication number | Publication date |
---|---|
BRPI0713221B1 (en) | 2020-11-17 |
FR2903604B1 (en) | 2008-09-05 |
US20110318396A1 (en) | 2011-12-29 |
US9060948B2 (en) | 2015-06-23 |
FR2903604A1 (en) | 2008-01-18 |
BRPI0713221A2 (en) | 2012-04-10 |
BRPI0713221B8 (en) | 2021-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2656451C (en) | Composition comprising a retinoid and benzoyl peroxide | |
US8241649B2 (en) | Dermatological/cosmetic gels comprising at least one retinoid and/or retinoid salt and benzoyl peroxide | |
US10925814B2 (en) | Cream gels comprising at least one retinoid and benzoyl peroxide | |
AU2002364437B2 (en) | Gel comprising at least a retinoid and benzoyl peroxide | |
US20110003894A1 (en) | Dermatological compositions comprising retinoids, dispersed benzoyl peroxide and carrageenans | |
US9060948B2 (en) | Dermatological/cosmetic compositions comprising a retinoid and benzoyl peroxide | |
US20050288374A1 (en) | Chemical stabilization of solubilized retinoids and aqueous compositions comprised thereof | |
ZA200505124B (en) | Process for the chemical stabilization of a solubilized retinoid in a solvent using a base |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GALDERMA RESEARCH & DEVELOPMENT, FRANCE Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LOUIS, FABIENNE;WILLCOX, NATHALIE;SEGURA-ORSONI, SANDRINE;REEL/FRAME:022799/0567;SIGNING DATES FROM 20090421 TO 20090510 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |